Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study

Kappos L., Gold R., Miller D. H., MacManus D. G., Havrdova E., Limmroth V., ...More

MULTIPLE SCLEROSIS JOURNAL, vol.18, no.3, pp.314-321, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 3
  • Publication Date: 2012
  • Doi Number: 10.1177/1352458511421054
  • Journal Name: MULTIPLE SCLEROSIS JOURNAL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.314-321
  • Istanbul University Affiliated: Yes

Abstract

Background: In a phase 2b study in patients with relapsing-remitting MS (RRMS), BG-12 240 mg three times daily significantly reduced the number of new gadolinium-enhanced (Gd+) lesions from weeks 12 to 24 (primary end point) by 69% compared with placebo.